表紙
市場調查報告書

COVID-19緩和產品的全球市場:未來展望 (2020∼2027年)

Global COVID-19 Mitigation Products Market - 2020-2027

出版商 DataM Intelligence 商品編碼 955727
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
COVID-19緩和產品的全球市場:未來展望 (2020∼2027年) Global COVID-19 Mitigation Products Market - 2020-2027
出版日期: 2020年08月31日內容資訊: 英文
簡介

由於新型冠狀病毒感染疾病 (COVID-19)的世界規模感染擴大,緩和其症狀的產品、服務的需求正在擴大。FDA (美國食品藥物管理局) 等行政機關醫療產業和製藥、醫療設備業,更與其外側的組織一起進行合作,致力於必要的器材圓滑的流通。尤其是拋棄式面罩和PPE (個人防護裝備),人工呼吸器等的採購急迫。

本報告提供全球COVID-19緩和產品的市場相關分析,市場基本結構及最新形勢,整體市場趨勢預測 (今後8年份),各類別 (診斷用品,加護治療設備,ICT,醫藥品,個人防護設備等) 及生產各設備、各終端用戶、各地區的詳細趨勢,主要的推動及阻礙市場要素,市場競爭結構,主要企業的簡介、事業策略等相關調查。

目錄

第1章 全球COVID-19緩和產品市場:分析方法、範圍

第2章 全球COVID-19緩和產品市場:定義和概要

第3章 全球COVID-19緩和產品市場:摘要整理

第4章 全球COVID-19緩和產品市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響力分析

第5章 全球COVID-19緩和產品市場:產業分析

  • 波特的五力分析
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • SWOT分析
  • 技術進步
  • 供需分析
  • 法規分析
  • 未滿足需求

第6章 全球COVID-19緩和產品市場:診斷產品/服務

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:診斷產品/服務的情況
  • 市場向心力指數:診斷產品/服務的情況
    • 血清檢測套組
    • 機器人式PCR檢查裝置/軟體
    • PCR檢查裝置/軟體
    • 鼻用、口用棉花棒
    • PCR檢驗用試劑、消耗品
    • 自我採取型PCR檢測套組
    • X光治療
    • 遠隔式溫度檢測
    • 超音波檢驗
    • CT治療
    • PACS (醫療圖像保存系統)、遠隔放射線診斷
    • FDG-PET/CT治療,污水實驗
    • 其他

第7章 全球COVID-19緩和產品市場:加護治療產品/服務

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:加護治療產品/服務的情況
  • 市場向心力指數:加護治療產品/服務的情況
    • 侵入性人工呼吸器
    • 非侵入性人工呼吸器
    • 可攜式人工呼吸器
    • 下一代型人工呼吸器
    • 腎臟透析
    • COVID-19居家醫療(硬體設備,軟體,服務)
    • 醫院的緊急應變能力、ICU
    • ECMO (體外式薄膜型人工肺) 治療
    • 其他

第8章 全球COVID-19緩和產品市場:醫療用ICT

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:醫療用ICT的情況
  • 市場向心力指數:醫療用ICT的情況
    • 電子醫療 (電子醫療)
    • 人工智慧 (AI),巨量資料,深層學習 (DL)
    • 區塊鏈技術
    • 地表監測系統/服務
    • 家庭治療用IT
    • 其他

第9章 全球COVID-19緩和產品市場:醫藥品

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:醫藥品的狀況
  • 市場向心力指數:醫藥品的狀況
    • 疫苗
    • 治療藥
    • 其他

第10章 全球COVID-19緩和產品市場:個人防護設備

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:個人防護設備的情況
  • 市場向心力指數:個人防護設備的情況
    • 醫療用手套
    • 醫療用面膜
    • 醫療用隔離衣
    • 手手指用、臉用的消毒劑
    • 醫療用臉屏蔽
    • 殺菌設備、消耗品
    • 眼球的保護
    • 其他

第11章 全球COVID-19緩和產品市場:COVID-19相關製造廠房

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:COVID-19相關製造廠房的情況
  • 市場向心力指數:COVID-19相關製造廠房的情況
    • 人工呼吸器
    • 血清檢測套組
    • 自我採取型PCR檢測套組
    • PCR檢驗用試劑
    • PCR檢查裝置
    • 手套
    • 防護裝備用隔離衣
    • 面膜
    • 臉屏蔽
    • 熔噴式PPE布料
    • 紡粘式PPE布料
    • 鼻子用、口用棉花棒
    • 醫療用玻璃,其他
    • 研究開發用設備、消耗品
    • 其他

第12章 全球COVID-19緩和產品市場:各終端用戶

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:各終端用戶
  • 市場向心力指數:各終端用戶
    • 醫院
    • 急救醫療服務(EMS)
    • 臨床檢驗室
    • 研究機關
    • 家庭看護設施
    • 診所
    • 其他

第13章 全球COVID-19緩和產品市場:各地區

  • 簡介
  • 市場規模的分析與對前一年 (YoY) 成長率:各地區
  • 市場向心力指數:各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第14章 全球COVID-19緩和產品市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 企業合併、收購 (M&A)的分析

第15章 全球COVID-19緩和產品市場:企業簡介

  • 3M Company
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Abbott
  • Agilent Technologies
  • Medtronic
  • Pfizer
  • Qualaris Healthcare Solutions
  • Allscripts Healthcare Solutions
  • Agfa Healthcare
  • AbCellera
  • 3Scan
  • Sanofi
  • Advenio Technosys
  • Siemens
  • Amara Health Analytics
  • Regeneron Pharmaceuticals
  • Avalon
  • Eli Lilly
  • Merck
  • Koninklijke Philips NV
  • 其他

第16章 全球COVID-19緩和產品市場:重要考察

第17章 關於DataM Intelligence

目錄

Market Overview

The COVID-19 global pandemic has increased the demand for essential mitigation products and services. COVID-19 has put the pressure on medtech and pharmaceutical industry with high demand for diagnostic tests, vaccines, ventilators, personal protective equipment (PPE), and other essential medical supplies. They are taking extraordinary measures to rapidly ramp up manufacturing capacity and capabilities by adopting several strategies such as partnerships with companies outside the sector, open-source equipment layout, and deployment of medically trained employees to support public-health needs. The global COVID-19 mitigation products size was worth US$ XX billion in 2019 and is estimated to reach US$ XX trillion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Market Dynamics

The global COVID-19 mitigation market is growing due to several factors such as rising demand for COVID-19 vaccine, growing awareness towards protection from COVID-19 globally and rising government and non-government organizations initiatives to meet the global demand for diagnostics, protection, and other products related to COVID-19. With high COVID-19 emergencies, the FDA has taken several proactive steps to remain in contact with medical device manufacturers and others in the supply chain, including hospitals and group purchasing organizations. The FDA has reached out to over 1,000 device manufacturing sites globally, focusing on the essential devices and services. The outreach has focused on two main types of essential devices: those that are in high demand due to the COVID-19 pandemic outbreak, such as PPE and ventilators, and devices that may be prone to a potential shortage if there is a supply disruption. The FDA issued a EUA to increase the supply of filtering facepiece respirators by authorizing the use of certain imported disposable respirators that are not National Institute for Occupational Safety and Health (NIOSH)-approved for use by health care professionals. Hence, with increasing such efforts and strategies to increase the availability of devices and services, the market is expected to grow over the forecast period worldwide.

Segment Analysis

The COVID-19 pandemic is projected to show positive growth in different markets including, diagnostic products & services, pharma industry products, intensive care products & services, personal & protection gear, medical ICT, and COVID-19 related manufacturing plant.

The intensive care product & services include invasive mechanical ventilators, noninvasive ventilators, portable ventilators, next-generation ventilators, kidney dialysis, COVID-19 homecare (HW, SW, services), surge capacity hospitals & ICUs, extracorporeal membrane oxygenation procedures, and others.

Advancement in mechanical ventilators aimed to provide improved services, settling on better choices, and improving patient's comfort alongside blending of pathophysiology, medicine, and engineering to enhancing the quality of medical care in respiratory distresses. To meet rising demand worldwide, all ventilator manufacturers are ramping up their production, analyzing the criticality of the situation, even other companies such as various leading US-based car manufacturing companies are also considering manufacturing ventilators by teaming up with ventilator manufacturing companies to set up as many units as much as possible. It is estimated that in April 2020 that over 900,000 ventilators were in demand worldwide, with a shortage of 80,000 in the U.S. alone. Major companies that provide the U.S. with the devices include General Electric Co., Medtronic PLC, Hill-Rom Holdings Inc., ResMed Inc. and Sweden's Getinge AB are adopting various strategies to meet the rising demand. For instance, in the first three months of 2020, Dragerwerk AG & Co. KGaA saw a sharp rise, increasing by 116.7%. In the medical division, orders rose by 177.2%, driven primarily by demand for ventilators. On March 30th 2020, Smiths Group has made a contract with the UK Government for a significant ramp-up in the production of its life-saving Smiths Medical paraPAC plus™ ventilators. Production is expected to grow rapidly with increase from hundreds a month to thousands a month to fulfil 10,000 units in response to the UK Government's challenge to UK technology and engineering businesses to help save lives in the coronavirus pandemic.

The pharma industry is expected to grow significantly over the forecast period due to ongoing clinical trials for COVID-19 vaccine. In August 2020, about 172 economies are engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries globally equal access to safe and effective vaccines, when they are licensed and approved. COVAX has the largest and most diverse COVID-19 vaccine portfolio globally, including nine candidate vaccines, with a further nine under evaluation and conversations underway with other major producers. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO), in partnership with developed and developing country vaccine manufacturers. It is the only worldwide initiative working with governments and manufacturers to ensure COVID-19 vaccines are available globally to both higher-income and lower-income countries.

Geographical Analysis

North America region is estimated to dominate the global COVID-19 mitigation products accounting for the largest market share over the forecast period. The rate of coronavirus deaths per 100,000 people in the U.S. is lower than in several European countries. By 2019, the U.S. healthcare spending stood at $3.3 trillion, more than 42% of global healthcare expenditures. By March 2020 Congress approved an unprecedented $2.2 trillion COVID-19 first relief package. It includes $161 Billion to the VA, CDC, FDA, Medicare, the Strategic National Stockpile and COVID-19 Vaccines. It does not cover the monthly deficit of $50 Billion that the Hospitals Managers Association reported. In August 2020, CDC has developed two laboratory tests that identify SARS-CoV-2, the virus that causes COVID-19. The newer of these tests are also used to test for influenza A and B viruses. Testing for all the three viruses at the same time will provide public health officials with the information they need to help reduce the spread of these viruses in the community while conserving resources that are in short supply.

Latin America has become a prime location for global COVID-19 vaccine trials, with the widespread of the virus in the community allowing developers to test the efficiency of their vaccines. Mexico is also carrying out late-stage trials for France's Sanofi, U.S. pharmaceutical giant Johnson & Johnson and two Chinese companies.

Competitive Landscape

The COVID-19 mitigation products is highly competitive and consists of several major players and emergence of new players in the market. Some of the players in the global COVID-19 mitigation products market are: 3M Company, Abbott, Sanofi, Pfizer, Eli Lilly, Merck, 3Scan, Advenio Technosys, Amara Health Analytics, Avalon, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, which are contributing to the growth of the COVID-19 Mitigation Products globally. For instance,

  • On November 11th 2019, Nihon Kohden has debuted its NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for neonates through adults. The ventilator features an integrated touchscreen, intuitive user interface, and onscreen help functions.
  • On April 2nd 2020, Clensta International, a leading biotechnology company has launched the Clensta Instant Hand Hygiene Solution; an advance formula for hand sanitization. The novel product offers instant 99.9% germ protection with antimicrobial and antiseptic properties that will establish the new product as a quick solution for all-round protection and freshness.
  • In March 2020, Regeneron Pharmaceuticals and Sanofi launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara (sarilumab) as a treatment for severe COVID-19 coronavirus infection in up to 400 patients.

Why Purchase the Report?

  • Visualize the composition of the COVID-19 mitigation products market by diagnostic products and services, pharma industry products, intensive care products & services, personal & protection gear, medical ICT, COVID-19 related manufacturing plants, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in COVID-19 mitigation products by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of COVID-19 mitigation products - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global COVID-19 mitigation products report would provide an access to an approx. 58 market data table, 54 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global COVID-19 Mitigation Products Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global COVID-19 Mitigation Products - Market Definition and Overview

3. Global COVID-19 Mitigation Products - Executive Summary

  • 3.1. Market Snippet by Diagnostic Products and Services
  • 3.2. Market Snippet by Intensive Care Products & Services
  • 3.3. Market Snippet by Pharma Industry Products
  • 3.4. Market snippet by Medical ICT
  • 3.5. Market Snippet by Personal & Protection Gear
  • 3.6. Market Snippet by COVID-19 Related Manufacturing Plant
  • 3.7. Market Snippet by End-User
  • 3.8. Market Snippet by Region

4. Global COVID-19 Mitigation Products - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand due to COVID-19 pandemic
      • 4.1.1.2. Growing research & development
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled professionals and capital
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global COVID-19 Mitigation Products - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. SWOT analysis
  • 5.6. Technological Advancements
  • 5.7. Supply & Demand Analysis
  • 5.8. Regulatory Analysis
  • 5.9. Unmet Needs

6. Global COVID-19 Mitigation Products - By Diagnostic Products and Services

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
  • 6.3. Market Attractiveness Index, By Diagnostic Products and Services Segment
    • 6.3.1. Serologic Test Kits*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Robotic PCR Systems & Software
    • 6.3.3. PCR Instrumentation & Software
    • 6.3.4. Nose & Mouth Swabs
    • 6.3.5. PCR Reagents & Consumables
    • 6.3.6. Self-collection PCR Test Kits
    • 6.3.7. X-Ray Procedures
    • 6.3.8. Standoff Thermometry
    • 6.3.9. Ultrasound Procedures
    • 6.3.10. CT Procedures
    • 6.3.11. PACS & Teleradiology
    • 6.3.12. FDG-PET/CT Procedures & Wastewater Testing
    • 6.3.13. Others

7. Global COVID-19 Mitigation Products - By Intensive Care Products & Services

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
  • 7.3. Market Attractiveness Index, By Intensive Care Products & Services Segment
    • 7.3.1. Invasive Mechanical Ventilators*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Noninvasive Ventilators
    • 7.3.3. Portable Ventilators
    • 7.3.4. Next Generation Ventilators
    • 7.3.5. Kidney Dialysis
    • 7.3.6. COVID-19 Homecare (HW, SW, Services)
    • 7.3.7. Surge Capacity Hospitals & ICUs
    • 7.3.8. Extracorporeal Membrane Oxygenation Procedures
    • 7.3.9. Others

8. Global COVID-19 Mitigation Products - By Medical ICT

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT Segment
  • 8.3. Market Attractiveness Index, By Medical ICT Segment
    • 8.3.1. E-Health*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. AI, Big Data & Deep Learning
    • 8.3.3. Blockchain Technologies
    • 8.3.4. Geo-Surveillance Systems & Services
    • 8.3.5. Homecare IT
    • 8.3.6. Others

9. Global COVID-19 Mitigation Products - By Pharma Industry Products

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products Segment
  • 9.3. Market Attractiveness Index, By Pharma Industry Products Segment
    • 9.3.1. Vaccines*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Therapeutic Drugs
    • 9.3.3. Others

10. Global COVID-19 Mitigation Products - By Personal & Protection Gear

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear Segment
  • 10.3. Market Attractiveness Index, By Personal & Protection Gear Segment
    • 10.3.1. Medical Gloves*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Medical Face Masks
    • 10.3.3. Medical PPE Gowns
    • 10.3.4. Hand & Surface Sanitizers
    • 10.3.5. Medical Face Shields
    • 10.3.6. PPE Sterilization: Systems & Consumables
    • 10.3.7. Medical Eye Protection
    • 10.3.8. Others

11. Global COVID-19 Mitigation Products - By COVID-19 Related Manufacturing Plant

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant Segment
  • 11.3. Market Attractiveness Index, By COVID-19 Related Manufacturing Plant Segment
    • 11.3.1. Ventilators*
      • 11.3.1.1. Introduction
      • 11.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 11.3.2. Sorologic Test Kits
    • 11.3.3. Self-collection PCR Test Kits
    • 11.3.4. PCR Reagents
    • 11.3.5. PCR Systems
    • 11.3.6. Gloves
    • 11.3.7. PPE Gowns
    • 11.3.8. Face Masks
    • 11.3.9. Face Shields
    • 11.3.10. Melt-Blown PPE Fabric
    • 11.3.11. Spun-Bond PPE Fabric
    • 11.3.12. Nose & Mouth Swabs
    • 11.3.13. Medical Glass & Other
    • 11.3.14. R&D Equipment & Consumables
    • 11.3.15. Others

12. Global COVID-19 Mitigation Products - By End-User

  • 12.1. Introduction
  • 12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 12.3. Market Attractiveness Index, By End-User Segment
    • 12.3.1. Hospitals*
      • 12.3.1.1. Introduction
      • 12.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 12.3.2. Emergency Medical Services (EMS)
    • 12.3.3. Clinical Labs
    • 12.3.4. Research Bodies
    • 12.3.5. Homecare & Nursing Homes
    • 12.3.6. Clinics
    • 12.3.7. Others

13. Global COVID-19 Mitigation Products - By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.2.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.2.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.2.10.1. U.S.
      • 13.2.10.2. Canada
      • 13.2.10.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.3.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.3.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.3.10.1. Germany
      • 13.3.10.2. U.K.
      • 13.3.10.3. France
      • 13.3.10.4. Italy
      • 13.3.10.5. Spain
      • 13.3.10.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.4.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.4.10.1. Brazil
      • 13.4.10.2. Argentina
      • 13.4.10.3. Rest of South America
  • 13.5. Asia Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.5.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 13.5.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 13.5.10.1. China
      • 13.5.10.2. India
      • 13.5.10.3. Japan
      • 13.5.10.4. Australia
      • 13.5.10.5. Rest of Asia Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 13.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 13.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 13.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 13.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 13.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 13.6.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 13.6.10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

14. Global COVID-19 Mitigation Products - Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Global COVID-19 Mitigation Products- Company Profiles

  • 15.1. 3M Company*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Key Highlights
    • 15.1.4. Financial Overview
  • 15.2. Abbott
  • 15.3. Agilent Technologies
  • 15.4. Medtronic
  • 15.5. Pfizer
  • 15.6. Qualaris Healthcare Solutions
  • 15.7. Allscripts Healthcare Solutions
  • 15.8. Agfa Healthcare
  • 15.9. AbCellera
  • 15.10. 3Scan
  • 15.11. Sanofi
  • 15.12. Advenio Technosys
  • 15.13. Siemens
  • 15.14. Amara Health Analytics
  • 15.15. Regeneron Pharmaceuticals
  • 15.16. Avalon
  • 15.17. Eli Lilly
  • 15.18. Merck
  • 15.19. Koninklijke Philips NV
  • 15.20. Others

LIST NOT EXHAUSTIVE

16. Global COVID-19 Mitigation Products - Premium Insights

17. Global COVID-19 Mitigation Products - DataM

  • 17.1. Appendix
  • 17.2. About Us and Services
  • 17.3. Contact Us